

## AMENDMENT

### Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:


Claim 1 (Canceled)

Claim 2 – (Cancel)

Claim 3 – 11 (Canceled)

Claim 12 – 18 (Cancel)

19. (Currently Amended) A compound having the formula:



Wherein:

$\text{X}$  is  $\text{CH}$ ;

$\text{Y}$  is oxygen;

$\text{Z}$  is oxygen;

$\text{R}$  is  $\text{CO}_2\text{H}$ ;

$\text{R}^2$  is and  $\text{R}^3$  are the same and are methyl or methoxy;

~~$\text{R}^3$  is methyl;~~

$\text{R}^4$  is phenyl;

$\text{R}^5$  is phenyl; and

$\text{R}^6$  is methyl,

or a pharmaceutically acceptable salt thereof.

Claims 20 – 52 (Cancel)

- 53. (New) A method of treating a disease where antagonism of the endothelin receptor is beneficial comprising administering a formulation of ambrisentan or darusentan in an amount and in a route sufficient to ameliorate the symptoms of said disease.
- 54. (New) The method of claim 53, wherein said disease is one or more of hypertension, pulmonary hypertension, acute myocardial infarction, Raynaud's syndrome, atherosclerosis, asthma, angina pectoris, acute kidney failure, renal insufficiency, cerebral vasospasms, cerebral ischemia, subarachnoid hemorrhages, migraine, endotoxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty, benign prostate hyperplasia, hypertension caused by ischemia or intoxication, kidney failure caused by ischemia or intoxication.
- 55. (New) The method of claim 53 wherein the endothelin receptor is the A type receptor.
- 56. (New) The method of claim 53, wherein the route is oral, parenteral, subcutaneous, intravenous, intramuscular, or intraperitoneal.
- 57. (New) The method of claim 56, wherein the oral route further comprises the use of a vapor, spray or propellant.